| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $83,197,477 ) (Continued on the next page) |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS126921 | Chemical Genetic Dissection of SWI/SNF Chromatin Remodeling Complex Functions in Cerebral Cortex Development | 001 | 2 | NIH | 4/8/2024 | $37,956 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS126921 | Chemical Genetic Dissection of SWI/SNF Chromatin Remodeling Complex Functions in Cerebral Cortex Development | 000 | 2 | NIH | 3/21/2024 | $488,007 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 001 | 4 | NIH | 3/13/2024 | $224,101 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA276888 | Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer | 000 | 2 | NIH | 3/5/2024 | $173,016 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA277194 | Effects of Exercise on Changes in Cardiovascular Biomarkers in Patients with Breast Cancer During Anthracycline-based Chemotherapy | 000 | 2 | NIH | 12/14/2023 | $88,500 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA278599 | Mechanisms of racial disparity in breast cancer-related lymphedema | 001 | 2 | NIH | 4/16/2024 | $36,727 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA278599 | Mechanisms of racial disparity in breast cancer-related lymphedema | 000 | 2 | NIH | 1/11/2024 | $661,096 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270116 | Targeting plasticity in lung cancer | 001 | 2 | NIH | 4/16/2024 | $29,192 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270116 | Targeting plasticity in lung cancer | 000 | 2 | NIH | 1/12/2024 | $525,461 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA271186 | Probabilistic Multiscale Modeling of the Tumor Microenvironment | 001 | 2 | NIH | 4/17/2024 | $32,586 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA271186 | Probabilistic Multiscale Modeling of the Tumor Microenvironment | 000 | 2 | NIH | 12/21/2023 | $586,532 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA279264 | Mechanisms of adaptation and resistance to emerging therapies for lung cancer | 000 | 2 | NIH | 4/3/2024 | $488,477 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA276946 | Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer | 001 | 2 | NIH | 4/17/2024 | $25,710 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA276946 | Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer | 000 | 2 | NIH | 11/6/2023 | $462,767 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA279922 | Defining the role of GNAS in gastrointestinal metastasis | 000 | 2 | NIH | 3/11/2024 | $268,826 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA266931 | The role of the novel interface cell state in melanoma invasion | 000 | 2 | NIH | 3/6/2024 | $173,016 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA277562 | Causal determinants of drug resistance and metastasis in cancer with multimodal single cell data | 000 | 2 | NIH | 1/8/2024 | $115,926 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA266068 | Mathematical modeling of metabolism rewiring in cancer eco-evolution and metastasis tropism | 001 | 2 | NIH | 4/18/2024 | $28,785 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA266068 | Mathematical modeling of metabolism rewiring in cancer eco-evolution and metastasis tropism | 000 | 2 | NIH | 12/21/2023 | $518,111 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG080684 | Molecular mechanisms of gamma-secretase modulation central to Alzheimer?s disease | 000 | 2 | NIH | 11/10/2023 | $729,119 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA269733 | TOX-driven CD8 T cell differentiation and dysfunction in tumors | 001 | 2 | NIH | 4/17/2024 | $30,396 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA269733 | TOX-driven CD8 T cell differentiation and dysfunction in tumors | 000 | 2 | NIH | 12/12/2023 | $547,139 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA276200 | Defining the function of Complex I truncating mutations in cancer | 001 | 2 | NIH | 4/17/2024 | $31,724 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA276200 | Defining the function of Complex I truncating mutations in cancer | 000 | 2 | NIH | 12/15/2023 | $571,016 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21AR081076 | Role of epidermis in regulating inflammatory skin manifestations of post-surgical lymphedema | 000 | 2 | NIH | 12/4/2023 | $175,230 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08DK132518 | Control of Intestinal Epithelial Function through Lymphatic-Intestinal Stem Cell Communication | 004 | 3 | NIH | 2/23/2024 | $167,617 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA262675 | Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy | 001 | 3 | NIH | 4/17/2024 | $34,382 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA262675 | Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy | 000 | 3 | NIH | 3/25/2024 | $618,874 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 000 | 3 | NIH | 2/25/2024 | $661,339 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM144508 | Mechanisms of enhancer-promoter communication, genome organization and transcription control | 000 | 3 | NIH | 4/4/2024 | $435,861 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA259533 | The role of B-cells in the anti-tumor immune response in triple negative breast cancer | 000 | 3 | NIH | 4/16/2024 | $264,185 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 003 | 3 | NIH | 4/18/2024 | $63,653 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 002 | 3 | NIH | 4/3/2024 | $0 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 3 | NIH | 3/14/2024 | $1,038,123 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K00CA245471 | Investigating the Role of Cell Plasticity in Malignant Transformation | 000 | 5 | NIH | 3/1/2024 | $96,890 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM144046 | Regulation of protein multi-functionality by 3 UTRs | 000 | 3 | NIH | 12/1/2023 | $637,200 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA283664 | The crosstalk between obesity-induced fatty liver and liver metastasis | 000 | 1 | NIH | 3/29/2024 | $139,125 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290231 | Targeting isocitrate dehydrogenase mutations by enzyme hyperactivation | 000 | 1 | NIH | 2/1/2024 | $474,760 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA284134 | Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast cancer risk | 000 | 1 | NIH | 4/2/2024 | $362,466 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21GM152950 | Recombinase polymerase amplification to enable same-cell, DNA/RNA multi-omic single cell sequencing | 000 | 1 | NIH | 12/27/2023 | $265,500 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM152017 | Teaching free energy calculations to learn | 000 | 1 | NIH | 2/19/2024 | $538,560 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC?Skin Imaging?Repository Enhancements for Promoting Interoperability and Utilization | 000 | 1 | NIH | 3/15/2024 | $715,146 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA286801 | Quantitatively predicting drug-resistant mutations to improve precision oncology | 000 | 1 | NIH | 1/26/2024 | $144,056 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA286330 | Acupuncture to Improve Outcomes in Patients with Sepsis: a Randomized Controlled Trial | 000 | 1 | NIH | 3/8/2024 | $205,700 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA286680 | PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer | 000 | 1 | NIH | 3/18/2024 | $88,000 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P01AI179406 | Understanding the molecular mechanisms regulating fungal colonization and disease in the mammalian intestinal niche | 000 | 1 | NIH | 3/27/2024 | $2,527,410 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 000 | 1 | NIH | 3/14/2024 | $135,224 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21DK137146 | Noninvasive Measurement of Voxelwise Renal Oxygenation Using Quantitative Susceptibility Mapping | 000 | 1 | NIH | 4/24/2024 | $220,000 |
| 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012973 | Molecular recording to understand the determinants of cell fate transitions in early development | 000 | 2 | NIH | 3/15/2024 | $224,101 |
|